Elevance Health's fundamentals are stabilizing after a volatile 2025, with the combined ratio improving to 95.9% in 2026Q2 from 98.8% in 2025Q4, but the sharp deceleration in revenue growth to 1.4% year-over-year and an implausibly low 10.9% loss ratio in 2026...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth decelerated sharply to 1.4% in 2026Q2 from 14.8% in 2025Q1, while the combined ratio improved to 95.9% from 98.8% in 2025Q4, but the anomalous 10.9% loss ratio in 2026Q2 raises questions about earnings quality.
Elevance Health has delivered a trailing‑12‑month EPS growth of 36.29%, placing it in the top 25% of its industry. This momentum underpins expectations for continued earnings expansion.
The company reports a return on equity of 12.90% and a gross profit margin of 100%, both ranking in the top 10% of its sector. These figures signal efficient capital use and high pricing power.
Elevance has increased its dividend for 15 straight years, yielding 2.42% today. The long‑term dividend track record supports a stable income stream for investors.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 15, 2026 | $7.45+20.0% vs $6.21 | $49.8B+1.9% vs $48.9B |
Q2 2026 Apr 22, 2026 | $12.58+16.3% vs $10.82 | $49.5B+2.7% vs $48.2B |
Q1 2026 Jan 28, 2026 | $3.33+7.4% vs $3.10 | $49.3B-1.1% vs $49.8B |
Q4 2025 Oct 21, 2025 | $6.03+22.3% vs $4.93 | $50.1B+1.4% vs $49.4B |
Elevance Health (NYSE: ELV - Get Free Report) issued an update on its FY 2026 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 27.000- for the period, compared to the consensus EPS estimate of 27.160. The company issued revenue guidance of -. Analysts Set New Price Targets A number of
Here is how Elevance Health (ELV) and American Well Corporation (AMWL) have performed compared to their sector so far this year.
Corient Private Wealth LP reduced its holdings in shares of Elevance Health, Inc. (NYSE: ELV) by 41.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,278 shares of the company's stock after selling 28,940 shares during the period.
Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Benchmark ELV against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Elevance Health Inc. (ELV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $402.43 | $87.27B | 16.02 | 12.62% | 2.84% | 13.25% | 1.71% | |
| $372.95 | $338.69B | 28.19 | 11.81% | 3.14% | 13.49% | — | |
| $87.10 | $111.13B | 62.66 | 7.85% | 1.18% | 6.41% | — | |
| $273.74 | $72.41B | 12.35 | 11.26% | 2.27% | 15.16% | — | |
| $371.93 | $44.65B | 37.80 | 10.06% | 0.88% | 6.89% | — | |
| $63.28 | $31.26B | -4.65 | 19.44% | -2.63% | -23.94% | — |
Elevance Health Inc. (ELV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Elevance Health Inc. (ELV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 15, 2026·SEC
Jun 10, 2026·SEC
May 13, 2026·SEC
Get notified when ELV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Elevance Health Inc. (ELV) stock FAQ — growth, dividends, profitability & financials explained
Elevance Health Inc. (ELV) grew revenue by 12.6% over the past year. This is steady growth.
Yes, Elevance Health Inc. (ELV) is profitable, generating $4.96B in net income for fiscal year 2025 (2.8% net margin).
Yes, Elevance Health Inc. (ELV) pays a dividend with a yield of 1.71%. This makes it attractive for income-focused investors.
Elevance Health Inc. (ELV) has a return on equity (ROE) of 13.3%. This is reasonable for most industries.
Elevance Health Inc. (ELV) has a combined ratio of 95.9%. A ratio below 100% indicates underwriting profitability.
